VERU - ベル （Veru Inc.）

MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVID-19 study results of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory

Oppenheimer said that a new analysis conducted by Veru (VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an EUA.

https://www.investing.com/news/pro/oppenheime-on-veru-inc--we-believe-this-update-will-provide-comfort-432SI-2862362

The share price of Veru Inc. (NASDAQ:VERU) fell to $11.87 per share on Monday from $12.10. While Veru Inc. has underperformed by -1.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERU rose by 72.78%, with highs and lows ranging from $18.40 to $4.34, whereas the […]

Veru Inc. (NASDAQ:VERU) price on Thursday, July 28, fall -3.10% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.21. A look at the stock’s price movement, the close in the last trading session was $12.60, moving within a range at $12.03 and $12.7447. The beta value (5-Year … Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think Read More »

The share price of Veru Inc. (NASDAQ:VERU) fell to $11.87 per share on Monday from $12.10. While Veru Inc. has underperformed by -1.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERU rose by 72.78%, with highs and lows ranging from $18.40 to $4.34, whereas the […]

Veru Inc. (NASDAQ:VERU) price on Thursday, July 28, fall -3.10% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.21. A look at the stock’s price movement, the close in the last trading session was $12.60, moving within a range at $12.03 and $12.7447. The beta value (5-Year … Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think Read More »

Veru Inc. (NASDAQ:VERU)’s traded shares stood at 6.48 million during the last session, with the company’s beta value hitting -0.30. At the close of trading, the stock’s price was $12.60, to imply an increase of 2.02% or $0.25 in intraday trading. The VERU share’s 52-week high remains $18.40, putting it -46.03% down since that peak … Veru Inc. (NASDAQ: VERU) Has Succeeded In Generating Interest In 2022, The Stock Is Up 113.92% Year-To-Date Read More »

MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that it will report financial results for its fiscal 2022 third quarter, on Thursday, August 11, 2022, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. ET to review the Company’s performance and to answer questions. The call will also be accessible via webcast.

Clinical-stage biotech Veru (VERU) announced on Monday that U.K

Veru (NASDAQ: VERU ) is set to discuss on May 10 with the Food and Drug Administration a pre-Emergency Use Authorization (EUA) meeting for its Phase 3 Covid-19 drug, sabizabulin (VERU-111). That could potentially be a turning point for Veru stock. However, the only problem is that there is a research report dated May 2 from a short-seller firm, Culper Research. The allegations the firm makes are of a nature that most potential investors in Veru stock are likely to read. To put bluntly the research report implies that Veru’s Phase 3 study is not likely to succeed in helping VERU-111 obtain a EUA. The report points out two major issues: first, the Phase 3 Covid-19 study contains “glaring issues, compounded by management misrepresentations.” For example, on April 11 Veru announced its Covid-19 drug brought down the mortality rate by 55% but the Culper report said that this was a manipulation of how high mortality rates were with Covid-19. Also, apparently, most of the patients in the study were outside of the U.S.

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve''s 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB ), considered a proxy for the sector, shed close to 3 percent during the week. Penny stock and digital therapeutics company Better Therapeutics, Inc. (NASDAQ: BTTX ) more than doubled despite a lack of any meaningful catalysts. On the other hand, Connect Biopharma Holdings Limited (NASDAQ: CNTB ) lost more than half its market value after its investigational asset that is being evaluated for ulcerative colitis flunked a mid-stage trial. Earnings news flow also continued to move stocks in the space. Here are the key catalysts for biotech stocks in the unfolding week: Conferences World Federation of Hemophilia, or WFH, 2022 World Congress: May 8-11, in Montreal, Canada, as well as virtually BofA Securities 2022 Healthcare Conference: May 9–13, in Las Vegas, Nevada Psych Symposium: May 11, in London, U.K.

A short-seller makes some worrying accusations against the company.

A whale with a lot of money to spend has taken a noticeably bearish stance on Veru . Looking at options history for Veru (NASDAQ: VERU ) we detected 21 strange trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 57% with bearish. From the overall spotted trades, 4 are puts, for a total amount of $184,800 and 17, calls, for a total amount of $776,914. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $17.5 for Veru … Full story available on Benzinga.com

Veru (VERU) stock has added 6.2% to $12.44 in Monday early trading, after the U.S